Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin)
Baumgärtel
M W
MW
Eichler
P
P
Glöckner
W M
WM
Ranze
O
O
Greinacher
A
A
D000906:Antibodies / Q000276:immunology; D000925:Anticoagulants / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000276:immunology* / Q000627:therapeutic use; D003429:Cross Reactions; D003871:Dermatan Sulfate / Q000276:immunology* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000276:immunology* / Q000627:therapeutic use; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology
D000906:Antibodies; D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; D006629:Hirudins; D011994:Recombinant Proteins; C035838:danaparoid; C083544:lepirudin